Effect of Respiratory Virus Infection on EmeRgencY Admission Study (EVERY Study)

Launched by INSTITUTE FOR CLINICAL EFFECTIVENESS, JAPAN · Jun 13, 2023

Keywords

ClinConnect Summary

The EVERY Study is a clinical trial designed to understand how infections caused by respiratory viruses, particularly Respiratory Syncytial Virus (RSV), affect patients who come to the emergency room with breathing issues. The researchers want to find out how common these infections are, what factors might increase the risk of getting them, and how they impact a patient's hospital stay. This study involves multiple hospitals and aims to gather information from patients who show respiratory symptoms, such as a runny nose, cough, or difficulty breathing.

To participate in this study, individuals must be 50 years or older and have been admitted to the emergency room with respiratory symptoms lasting at least 24 hours. Symptoms should have started within the last week. Participants will not be eligible if they are there for scheduled admissions, trauma care, or certain medical conditions that affect the throat. Those who join the study will help researchers learn more about respiratory infections and how to better treat patients in the future. It’s important to note that participation is voluntary, and patients can choose to opt out at any time.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Aged 50 years or older
• • Admission from emergency room
• • Having at least one of following respiratory symptoms/signs for at least 24 hours and the onset date of first symptom/sign less than 7 days before admission, which meet the acute respiratory infection (ARI) case definition described below: nasal congestion, rhinorrhea, sore throat, cough, sputum, dyspnea, wheeze, crackles or rhonchi, tachypnea (\>=20 per minute), decreased saturation of oxygen (\< 95%), admission with oxygen supplementation
• Exclusion Criteria:
• • Scheduled admission
• • Admission for trauma care
• • With nasopharyngeal cavity diseases or deformity which block the nasopharyngeal sampling
• • Admission for end of life
• • Decline to participate the study by either informed consent or opt-out method